Shareholder Information

Cambrex Corporation is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics.

We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage forms.

Stock Quote

CBM (Common Stock)
ExchangeNYSE (US Dollar)
Price$7.97
Change (%) Stock is Up 0.23 (2.97%)
Volume649,011
Data as of 01/27/12 4:01 p.m. ET
Minimum 20 minute delay
Refresh quote

Stock Chart

Stock chart for: 03NA000000CBM

Recent News more

01/27/12 - 4:51 p.m.
Cambrex Launches Commerical Sufentanil and Sufentanil Citrate
 
12/22/11 - 11:40 a.m.
Cambrex VP Elected to SOCMA Board of Governors
 
12/16/11 - 11:07 a.m.
Cambrex Manufacturing Facility Receives MHRA Approval
 
12/08/11 - 10:22 a.m.
Cambrex to Exhibit at InformexUSA 2012
 

Upcoming Eventsmore

There are currently no events scheduled.

Contact Information

Stephanie LaFiura
Investors Relations Associate
Phone: 201-804-3037
Fax: 201-804-9852
Email: stephanie.lafiura@cambrex.com

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
Phone: 718.921.8275
Fax: 718.921.8331
Email: cpino@amstock.com

BDO Seidman, LLP



Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.